Difference between revisions of "Sertraline-doxepine"
From Psychiatrienet
| (2 intermediate revisions by one other user not shown) | |||
| Line 3: | Line 3: | ||
| to = doxepin | | to = doxepin | ||
| stop = | | stop = | ||
| − | + | {{TCAdecrease25p3d}} | |
| − | |||
| start = | | start = | ||
| − | + | {{TCAincrease25p3d}} | |
| − | + | | info = | |
| − | + | {{TCAplasmalevelmonitoring}} | |
| − | |||
| − | | info = | ||
| − | |||
| − | {{ | ||
}} | }} | ||
Latest revision as of 13:14, 30 June 2023
| ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
Switch medication from sertraline to doxepin.[2] [3]
Stop sertraline - Day 1: Decrease with about 25% of the original dose per 3 days.
Start doxepin- Day 1: Increase with about 25% of target dose per 3 days.
More information- Plasma monitoring for TCA's is advisable, because of plasma-reponse relations, genetic polymorphism and under or overdosing.[4]
- ↑ 1.0 1.1 1.2 1.3 1.4 KNMP; Informatorium Medicamentorum 2023; Monografie "doxepine" (Dutch)
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
- ↑ (dutch) monografie.org tricyclische-antidepressiva
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
